(1-Methoxyethoxy)acetyl chloride | 922498-74-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: (1-Methoxyethoxy)acetyl chloride
• 英文别名: 2-(1-methoxyethoxy)acetyl chloride
• CAS: 922498-74-6
• 化学式: C₅H₉ClO₃
• 分子量: 152.57
• InChiKey: DHAPRAXCJXNDQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ENCAPSULATION OF VITAMIN C INTO WATER SOLUBLE DENDRIMERS
  申请人：Astruc Didier

  公开号：US20110021626A1

  公开（公告）日：2011-01-27

  The invention relates to a conjugated dendrimer that comprises at least one water-soluble dendrimer and at least one vitamin C molecule. The conjugated dendrimer can be used e.g. for preparing cosmetic or pharmaceutical compositions. The dendrimers have a good vitamin C load capacity and are biocompatible.

  该发明涉及一种共轭树状聚合物，包括至少一种水溶性树状聚合物和至少一个维生素C分子。该共轭树状聚合物可用于制备化妆品或药用组合物。这些树状聚合物具有良好的维生素C负载能力，并且具有生物相容性。
• [EN] ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES<br/>[FR] IMIDAZOQUINOLINES SUBSTITUEES PAR ARYLOXY ET ARYLALKYLENEOXY
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2005020999A1

  公开（公告）日：2005-03-10

  Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  在这个研究中，披露了在6、7、8或9位具有芳基氧基、芳基烷氧基或羟基取代基的咪唑喹啉化合物，包含这些化合物的药物组合物、中间体以及这些化合物作为免疫调节剂的使用方法，用于调节动物体内细胞因子生物合成，以及用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• Method for producing axial asymmetric compounds, intermediates for producing the same, complexes of transition metals with novel axial asymmetric compounds as the ligands, catalysts for asymmetric hydrogenation, and catalysts for forming asymmetric carbon-carbon bonds
  申请人：Takasago International Corporation

  公开号：US20010047110A1

  公开（公告）日：2001-11-29

  The invention provides a metal complex comprising a ligand and a metal. The ligand is an aminophosphine compound represented by the following formula (1) 1 [Each Ar represents an aryl group optionally substituted with a halogen atom, a lower alkyl group having 1 to 4 carbon atom or an alkoxy group, both Ar's being same or different with each other. R 1 and R 2 represent hydrogen atom, a cycloalkyl group having 5 to 7 carbon atoms, or an alkyl group having 1 to 6 carbon atom optionally substituted with a halogen atom, a lower alkoxy group or phenyl group, with R 1 and R 2 being same or different with each other. Alternatively, one of R 1 and R 2 is hydrogen atom and the other is —COR 3 (R 3 represents a cycloalkyl group having 5 to 7 carbon atoms, a lower alkyl group having 1 to 6 carbon atom optionally substituted with a halogen atom, a lower alkoxy group or phenyl group, a substituted or unsubstituted phenyl group, or a lower alkoxy group having 1 to 6 carbon atom optionally substituted with a cycloalkyl group having 5 to 7 carbon atoms, a halogen atom, a lower alkoxy group or phenyl group) or —SO 2 R 4 (R 4 represents a cycloalkyl group having 5 to 7 carbon atoms, an alkyl group optionally substituted with a halogen atom, a lower alkoxy group or phenyl group, or substituted or unsubstituted phenyl group). n represents 0]. The metal is rhodium, ruthenium, iridium or nickel.

  本发明提供了一种包含配体和金属的金属配合物。该配体是由以下式子（1）表示的氨基膦化合物组成：1[每个Ar代表一个芳基基团，可以选择地用卤原子、具有1到4个碳原子的较低烷基基团或烷氧基取代，两个Ar相同或不同。R1和R2代表氢原子，具有5到7个碳原子的环烷基团或具有1到6个碳原子的烷基基团，可以选择地用卤原子、较低烷氧基或苯基取代，其中R1和R2相同或不同。或者，R1和R2中的一个是氢原子，另一个是-COR3（R3代表具有5到7个碳原子的环烷基团、具有1到6个碳原子的较低烷基基团，可以选择地用卤原子、较低烷氧基或苯基取代，取代或未取代的苯基或具有5到7个碳原子的环烷基团、卤原子、较低烷氧基或苯基取代的具有1到6个碳原子的较低烷氧基）或-SO2R4（R4代表具有5到7个碳原子的环烷基团、可以选择地用卤原子、较低烷氧基或苯基取代的烷基，或取代或未取代的苯基）。n代表0。金属是铑、钌、铱或镍。
• Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines
  申请人：Lindstrom Kyle J.

  公开号：US20090018122A1

  公开（公告）日：2009-01-15

  Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

  本发明涉及一种咪唑喹啉化合物，其在6、7、8或9位具有芳氧基，芳基烷氧基或羟基取代基，以及含有该化合物的制药组合物，中间体和使用这些化合物作为免疫调节剂的方法，用于调节动物中的细胞因子生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• Acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20070015754A1

  公开（公告）日：2007-01-18

  There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基鸟氨酸化合物（I）或其立体异构体；或其药学上可接受的盐，其中R1、R2、R3、R4和R5如本文所定义，以及它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地抑制Aβ-肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生有关的神经系统疾病，例如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病的化合物。